Epigenomics AG (LON:0QXH)
0.8820
-0.0080 (-0.90%)
At close: Nov 14, 2025
Epigenomics AG Revenue
Epigenomics AG had revenue of 4.00K EUR in the half year ending June 30, 2025, a decrease of -98.03%. This brings the company's revenue in the last twelve months to 4.00K, down -97.06% year-over-year.
Revenue (ttm)
4.00K EUR
Revenue Growth
-97.06%
P/S Ratio
200.96
Revenue / Employee
2.00K EUR
Employees
2
Market Cap
689.10K GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 339.00K | -560.00K | -62.29% |
| Dec 31, 2022 | 899.00K | -5.30M | -85.51% |
| Dec 31, 2021 | 6.20M | 5.36M | 636.70% |
| Dec 31, 2020 | 842.00K | -283.00K | -25.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |